TLRY
Price
$1.19
Change
+$0.04 (+3.48%)
Updated
Sep 5 closing price
Capitalization
1.31B
24 days until earnings call
YCBD
Price
$0.73
Change
+$0.01 (+1.39%)
Updated
Sep 5 closing price
Capitalization
6.51M
Interact to see
Advertisement

TLRY vs YCBD

Header iconTLRY vs YCBD Comparison
Open Charts TLRY vs YCBDBanner chart's image
Tilray Brands
Price$1.19
Change+$0.04 (+3.48%)
Volume$41.19M
Capitalization1.31B
CBDMD
Price$0.73
Change+$0.01 (+1.39%)
Volume$57.52K
Capitalization6.51M
TLRY vs YCBD Comparison Chart in %
Loading...
TLRY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
YCBD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
TLRY vs. YCBD commentary
Sep 08, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is TLRY is a Hold and YCBD is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 08, 2025
Stock price -- (TLRY: $1.19 vs. YCBD: $0.73)
Brand notoriety: TLRY: Notable vs. YCBD: Not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: TLRY: 61% vs. YCBD: 60%
Market capitalization -- TLRY: $1.31B vs. YCBD: $6.51M
TLRY [@Pharmaceuticals: Generic] is valued at $1.31B. YCBD’s [@Pharmaceuticals: Generic] market capitalization is $6.51M. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $67.95B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $3.93B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

TLRY’s FA Score shows that 0 FA rating(s) are green whileYCBD’s FA Score has 1 green FA rating(s).

  • TLRY’s FA Score: 0 green, 5 red.
  • YCBD’s FA Score: 1 green, 4 red.
According to our system of comparison, YCBD is a better buy in the long-term than TLRY.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

TLRY’s TA Score shows that 4 TA indicator(s) are bullish while YCBD’s TA Score has 5 bullish TA indicator(s).

  • TLRY’s TA Score: 4 bullish, 4 bearish.
  • YCBD’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, both TLRY and YCBD are a good buy in the short-term.

Price Growth

TLRY (@Pharmaceuticals: Generic) experienced а -13.77% price change this week, while YCBD (@Pharmaceuticals: Generic) price change was -1.15% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +0.08%. For the same industry, the average monthly price growth was +12.00%, and the average quarterly price growth was +86.48%.

Reported Earning Dates

TLRY is expected to report earnings on Oct 02, 2025.

Industries' Descriptions

@Pharmaceuticals: Generic (+0.08% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
TLRY($1.31B) has a higher market cap than YCBD($6.51M). TLRY YTD gains are higher at: -10.526 vs. YCBD (-75.650). YCBD has higher annual earnings (EBITDA): 163K vs. TLRY (-2.13B). TLRY has more cash in the bank: 256M vs. YCBD (1.06M). YCBD has less debt than TLRY: YCBD (963K) vs TLRY (329M). TLRY has higher revenues than YCBD: TLRY (821M) vs YCBD (19M).
TLRYYCBDTLRY / YCBD
Capitalization1.31B6.51M20,074%
EBITDA-2.13B163K-1,305,247%
Gain YTD-10.526-75.65014%
P/E RatioN/A1.43-
Revenue821M19M4,321%
Total Cash256M1.06M24,151%
Total Debt329M963K34,164%
FUNDAMENTALS RATINGS
TLRY vs YCBD: Fundamental Ratings
TLRY
YCBD
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
52
Fair valued
48
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9999
PRICE GROWTH RATING
1..100
3594
P/E GROWTH RATING
1..100
941
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

YCBD's Valuation (48) in the Other Consumer Services industry is in the same range as TLRY (52) in the Biotechnology industry. This means that YCBD’s stock grew similarly to TLRY’s over the last 12 months.

YCBD's Profit vs Risk Rating (100) in the Other Consumer Services industry is in the same range as TLRY (100) in the Biotechnology industry. This means that YCBD’s stock grew similarly to TLRY’s over the last 12 months.

YCBD's SMR Rating (99) in the Other Consumer Services industry is in the same range as TLRY (99) in the Biotechnology industry. This means that YCBD’s stock grew similarly to TLRY’s over the last 12 months.

TLRY's Price Growth Rating (35) in the Biotechnology industry is somewhat better than the same rating for YCBD (94) in the Other Consumer Services industry. This means that TLRY’s stock grew somewhat faster than YCBD’s over the last 12 months.

YCBD's P/E Growth Rating (1) in the Other Consumer Services industry is significantly better than the same rating for TLRY (94) in the Biotechnology industry. This means that YCBD’s stock grew significantly faster than TLRY’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
TLRYYCBD
RSI
ODDS (%)
Bearish Trend 4 days ago
90%
Bullish Trend 4 days ago
79%
Stochastic
ODDS (%)
Bullish Trend 4 days ago
82%
Bearish Trend 4 days ago
90%
Momentum
ODDS (%)
Bullish Trend 4 days ago
85%
Bullish Trend 4 days ago
83%
MACD
ODDS (%)
Bearish Trend 4 days ago
90%
Bullish Trend 4 days ago
90%
TrendWeek
ODDS (%)
Bearish Trend 4 days ago
88%
Bearish Trend 4 days ago
90%
TrendMonth
ODDS (%)
Bullish Trend 4 days ago
82%
Bearish Trend 4 days ago
90%
Advances
ODDS (%)
Bullish Trend 14 days ago
83%
Bullish Trend 14 days ago
79%
Declines
ODDS (%)
Bearish Trend 5 days ago
90%
Bearish Trend 7 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 4 days ago
90%
Bullish Trend 4 days ago
75%
Aroon
ODDS (%)
Bullish Trend 4 days ago
83%
Bearish Trend 4 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
TLRY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
YCBD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
LSMIX14.310.15
+1.06%
Loomis Sayles Small/Mid Cap Growth Instl
BGIUX15.700.11
+0.72%
Baillie Gifford International Alpha 4
UBVRX83.620.37
+0.44%
Undiscovered Managers Behavioral Val R2
HDCEX10.01-0.01
-0.10%
Rational Equity Armor Fund C
FDERX24.44-0.13
-0.53%
Federated Hermes Equity Income R

TLRY and

Correlation & Price change

A.I.dvisor indicates that over the last year, TLRY has been loosely correlated with CGC. These tickers have moved in lockstep 63% of the time. This A.I.-generated data suggests there is some statistical probability that if TLRY jumps, then CGC could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To TLRY
1D Price
Change %
TLRY100%
+3.48%
CGC - TLRY
63%
Loosely correlated
+5.80%
CRON - TLRY
61%
Loosely correlated
N/A
OGI - TLRY
60%
Loosely correlated
+2.48%
ACB - TLRY
56%
Loosely correlated
+1.66%
ELAN - TLRY
32%
Poorly correlated
+5.50%
More

YCBD and

Correlation & Price change

A.I.dvisor indicates that over the last year, YCBD has been loosely correlated with AGYTF. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if YCBD jumps, then AGYTF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To YCBD
1D Price
Change %
YCBD100%
+1.44%
AGYTF - YCBD
39%
Loosely correlated
N/A
TLRY - YCBD
25%
Poorly correlated
+3.48%
DERM - YCBD
23%
Poorly correlated
-0.71%
CRON - YCBD
23%
Poorly correlated
N/A
SBFM - YCBD
21%
Poorly correlated
-5.24%
More